Title : Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.

Pub. Date : 2006 Jun

PMID : 16518603






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. Etoposide DNA damage inducible transcript 3 Homo sapiens
2 The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. Etoposide DNA damage inducible transcript 3 Homo sapiens
3 The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. Etoposide DNA damage inducible transcript 3 Homo sapiens